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Summary
 
Early in programmed cell death (apoptosis), mitochondrial membrane permeability increases.
This is at least in part due to opening of the permeability transition (PT) pore, a multiprotein
complex built up at the contact site between the inner and the outer mitochondrial mem-
branes. The PT pore has been previously implicated in clinically relevant massive cell death in-
duced by toxins, anoxia, reactive oxygen species, and calcium overload. Here we show that PT
pore complexes reconstituted in liposomes exhibit a functional behavior comparable with that
of the natural PT pore present in intact mitochondria. The PT pore complex is regulated by
thiol-reactive agents, calcium, cyclophilin D ligands (cyclosporin A and a nonimmunosuppres-
sive cyclosporin A derivative), ligands of the adenine nucleotide translocator, apoptosis-related
endoproteases (caspases), and Bcl-2–like proteins. Although calcium, prooxidants, and several
recombinant caspases (caspases 1, 2, 3, 4, and 6) enhance the permeability of PT pore-contain-
ing liposomes, recombinant Bcl-2 or Bcl-X
 
L
 
 augment the resistance of the reconstituted PT
pore complex to pore opening. Mutated Bcl-2 proteins that have lost their cytoprotective po-
tential also lose their PT modulatory capacity. In conclusion, the PT pore complex may consti-
tute a crossroad of apoptosis regulation by caspases and members of the Bcl-2 family.
 
T
 
wo different major changes in mitochondrial mem-
brane permeability have been observed during the ef-
fector phase of apoptosis. On the one hand, the electro-
chemical gradient built up on the mitochondrial inner
membrane dissipates early during apoptosis (1–4). On the
other hand, apoptogenic proteins that normally are seques-
tered in mitochondria are released via the outer mitochon-
drial membrane. Such proteins include cytochrome 
 
c
 
 (5–7)
and apoptosis inducing factor (AIF)
 
1
 
 (8, 9). The protoon-
cogene product Bcl-2 prevents the permeability increase in
both mitochondrial membranes (4, 6–10). Based on the
similarity of the effects of Bcl-2 and pharmacological inhib-
itors of the mitochondrial permeability transition (PT)
pore, we have advanced the hypothesis that opening of the
PT pore might be (co-)responsible for the apoptosis-associ-
ated changes in mitochondrial membrane function (2, 4, 8,
11). In isolated mitochondria, opening of the PT pore en-
tails both the disruption of the inner mitochondrial trans-
membrane potential (
 
Dc
 
m
 
) (12, 13) and the release of the
apoptogenic proteins AIF (8, 9) and cytochrome 
 
c
 
 (14, 15),
suggesting that the PT pore may have an important role in
cell death control. Moreover, opening of the PT pore has
been implicated in clinically relevant massive cell death of
hepatocytes, neurons, and myocardiocytes induced by hepato-
toxins, excitotoxins, calcium, reactive oxygen species, and
anoxia (3, 4, 12, 13, 16–18 and references cited therein).
If the mitochondrion fulfilled a major role in apoptosis
control, it should be capable of integrating very different
proapoptotic signal transduction and damage pathways. In
this context, it appears important that the PT pore is a dy-
namic multiprotein complex located at the contact site be-
tween the inner and the outer mitochondrial membranes,
one of the critical sites of metabolic coordination between
the cytosol, the mitochondrial intermembrane space, and
 
1
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the matrix. The PT pore participates in the regulation of
matrix Ca
 
2
 
1
 
, pH, 
 
Dc
 
m
 
, and volume and functions as a
Ca
 
2
 
1
 
-, voltage-, pH-, and redox-gated channel with sev-
eral levels of conductance and little if any ion selectivity
(12, 13, 19). Although the exact composition of the PT
pore complex (PTPC) is unknown, it is thought to involve
proteins from the cytosol (hexokinase), the outer mem-
brane (voltage-dependent anion channel [VDAC]), the in-
ner membrane (the adenine nucleotide translocator [ANT]),
and the matrix (cyclophilin D) (12, 13, 20–23). As a conse-
quence, the PT pore complex contains multiple targets for
endogenous regulators. In intact cells and isolated mito-
chondria, PT pore opening is induced by several proapop-
totic second messengers: Ca
 
2
 
1
 
, prooxidants, nitric oxide,
ceramide, and caspase 1 (1, 2, 8, 9, 12, 13, 19, 24–27).
Moreover, it is regulated by the antiapoptotic oncoproteins
Bcl-2 and Bcl-X
 
L
 
, which stabilize mitochondrial mem-
branes (4, 8, 9, 28–31), and by the proapoptotic Bcl-2 ana-
logue Bax, which disrupts the 
 
Dc
 
m
 
 (32).
It has been unclear whether these effectors specifically
act on PTPC, affect other mitochondrial structures not as-
sociated with PTPC (6, 7), or rather nonspecifically per-
turb membrane permeability, as this has been suggested for
members of the Bcl-2 family (32–35). To distinguish these
possibilities, we purified protein complexes containing PTPC,
reconstituted them in liposomes, and created a reduced ex-
perimental system that shares properties of the PT pore
studied in intact mitochondria or cells. Biochemical and
functional data indicate that PTPC enriched from brain
homogenates contain the proapoptotic Bcl-2 homologue
Bax (but not Bcl-2 and Bcl-X
 
L
 
), in addition to proteins
previously suggested to participate in the regulation of PT
(ANT, VDAC, cyclophilin D, and hexokinase). The mem-
brane permeability of PTPC liposomes was enhanced by
several inducers of PT including Ca
 
2
 
1
 
, prooxidants, and re-
combinant caspases. Recombinant Bcl-2 and Bcl-X
 
L
 
 act as
inhibitors of PT pore opening in this artificial system. Thus,
PTPC constitutes the target of multiple apoptosis regula-
tors, emphasizing its probable central role in cell death con-
trol.
 
Materials and Methods
 
Materials.
 
Recombinant human Bcl-X
 
L
 
 (1–209), Bcl-2 (1–
218), mutant Bcl-2 (Gly145Ala), and Bcl-2
 
Da
 
5/6 (
 
D
 
143–184),
all lacking the hydrophobic transmembrane domain (
 
D
 
219–239
in the case of Bcl-2; 
 
D
 
210–230 for Bcl-X
 
L
 
) and tagged NH
 
2
 
 ter-
minally with His
 
6
 
, were produced and purified as described (34).
Recombinant caspases were produced as active enzymes (36, 37).
Caspase activity is defined as amount of enzyme required to cleave 1
 
m
 
mol of the fluorogenic substrate Ac-DEVD.amc (acetyl-Asp-Glu-
Val-Asp-aminomethylcoumarin; caspases 3 and 6), Ac-YVAD.amc
(acetyl-Tyr-Val-Ala-Asp-aminomethylcoumarin; caspase 1), or
Ac-WEHD.amc (acetyl-Trp-Glu-His-Asp-aminomethylcoumarin;
caspase 4) per hour. Caspase substrates and inhibitors (Ac-DEVD.
cmk [acetyl-Asp-Glu-Val-Asp-chloromethylketone], Ac-YVAD.
cmk [acetyl-Tyr-Val-Ala-Asp-chloromethylketone]) were purchased
from Bachem (Basel, Switzerland). All remaining reagents were from
Sigma Chemical Co. (St. Louis, MO), unless specified differently.
 
Reconstitution of PTPCs in Liposomes.
 
PTPCs were purified and
reconstituted in liposomes following published protocols (22),
with several modifications (Fig. 1 
 
A
 
). In brief, four Wistar (Phila-
delphia, PA) rat brains (3–4-mo-old males, stored at 
 
2
 
80
 
8
 
C)
were homogenized in buffer 1 (1 mM 
 
a
 
-monothioglycerol, 10
mM glucose, pH 8.0, 40 ml; sample 
 
1
 
 in Fig. 1) and centrifuged
twice (15 min, 12,000 
 
g
 
, 4
 
8
 
C) to resuspend the pellet first in
buffer 1 alone, and then in buffer 1 plus 0.5% Triton X-100
(Boehringer Mannheim, Indianapolis, IN) for 30 min at room
temperature (RT) while stirring. Supernatants (40 min, 50,000 
 
g
 
,
4
 
8
 
C) of this mixture, the Triton-soluble protein fraction (sample
 
2
 
 in Fig. 1), were mixed with 17 g DE52 resin previously equili-
brated with buffer 2 (1.5 mM Na
 
2
 
HPO
 
4
 
, 1.5 mM K
 
2
 
HPO
 
4
 
, 100
mM glucose, 1 mM dithioerythitol, pH 8.0). These beads were
packed into an FPLC column (XK16/20; Pharmacia Biotech,
Uppsala, Sweden) and eluted with buffer 2 supplemented with 50
mM KCl (buffer 3) or 400 mM KCl (buffer 4). After equilibra-
tion with buffer 3 (0.8 ml/min, 6 ml), elution was performed on
a linear gradient from 50 to 400 mM KCl (buffers 3 versus 4), fol-
lowed by determination of hexokinase activity (sample 
 
3
 
 in Fig.
1). Lipid vesicles were prepared by mixing 300 mg phosphatidyl-
choline and 60 mg cholesterol in 3 ml chloroform, evaporation of
the chloroform under nitrogen, and resuspension in 3 ml 125 mM
sucrose 
 
1
 
 10 mM Hepes (pH 7.4) 
 
1
 
 0.3% 
 
n
 
-octyl-
 
b
 
-
 
d
 
-pyrano-
side by vortexing (90 min, RT). These vesicles (6 ml) were incu-
bated with 6 ml of PTPC-containing solution during 20 min at
RT and dialyzed overnight (4
 
8
 
C) against 125 mM sucrose 
 
1
 
 10
mM Hepes (pH 7.4). In several experiments, recombinant Bcl-2,
Bcl-X
 
L
 
, or mutated Bcl-2 proteins were added during the dialysis
step at a dose corresponding to 5% of the total PTPC proteins, as
determined in each experiment. Liposomes recovered from dialy-
sis were ultrasonicated (120 W, Ultrasonic Processor; Bioblock,
Illkirch, France) during 7 s in 5 mM malate and 10 mM KCl,
charged on a Sephadex G50 column (C16/20; Pharmacia Bio-
tech), and eluted with 125 mM sucrose 
 
1
 
 10 mM Hepes (pH 7.4,
0.8 ml/min) (Fig. 1 
 
C
 
). Proteins were extracted from the lipo-
some preparation (1 ml) by mixing with 2 ml 880 ml KCl 
 
1
 
 6 ml
chloroform/methanol (2:1 vol/vol) and recovered from the inter-
phase after standard methods (38), followed by resuspension in
0.1% SDS (sample 
 
4
 
 in Fig. 1). They were then precipitated with
80% (vol/vol) acetone for two-dimensional electrophoresis. A
mean of 1.86 
 
6
 
 0.24 
 
m
 
g protein/mg lipid (X 
 
6
 
 SD, 
 
n
 
 
 
5
 
 5) was
recovered from proteoliposomes. In several experiments, purified
rat cytochrome 
 
c
 
 (25 
 
m
 
g/ml, corresponding to 500 ng cytochrome
 
c
 
/mg lipid) was added before the sonication step, followed by two
washes on Sephadex G50 columns to remove excess cytochrome 
 
c
 
from the supernatant.
 
Determination of Calcein Efflux from PTPC Liposomes.
 
Liposomes
were generated as described above with the sole difference that
sonication was performed in 8 mM calcein (Molecular Probes
Inc., Eugene, OR) 
 
1
 
 10 mM cobalt chloride. 200 
 
m
 
l liposome
suspension was incubated for 90 min with different concentration
of atractyloside (Atr) and/or 50 
 
m
 
M bongkrekic acid (gift from
Hans J. Duine, Delft University, Delft, The Netherlands). The
supernatants of liposomes (4.5 
 
3
 
 10
 
6
 
 
 
g
 
, 45 min, 4
 
8
 
C) were recov-
ered, supplemented with EDTA (final concentration of 1 mM),
and subjected to fluorometric analysis (excitation at 488 nm,
emission at 520 nm) in a fluorescence spectrometer (F4500; Hita-
chi, Tokyo, Japan).
 
Western Blots and Two-dimensional Electrophoresis.
 
Total brain ho-
mogenates, Triton-soluble proteins, PTPC preparations from an-
ion exchange columns, and proteins extracted from PTPC-reconsti-
tuted liposomes were separated by SDS-PAGE (10–15%, 30 
 
m
 
g 
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protein/lane), followed by Western blot using monoclonal anti-
bodies recognizing cytochrome 
 
c
 
 (PharMingen, San Diego, CA;
reference 5), hsp60 (clone LK1; Sigma Chemical Co.), VDAC
(gift from F. Thinnes, Molecular Pathology Institute for Experi-
mental Medicine, Göttingen, Germany), or polyclonal rabbit an-
tisera against the ANT (gift from T. Wallimann, Zürich, Switzer-
land; reference 22), and the NH
 
2
 
 terminus of cyclophilin D (gift
from Paolo Bernardi, University of Padova, Padova, Italy; refer-
ence 20), F
 
1
 
 ATPase (provided by P.V. Vignais, Centre National
de la Recherche Scientifique, Grenoble, France; reference 1),
Bcl-2 (specific for residues 20–34; Calbiochem Corp., La Jolla,
CA), Bcl-X
 
L
 
 (Ab-1; Calbiochem Corp.), Bad, Bag-1, or Bax
(Santa Cruz Biotechnology, Santa Cruz, CA). In one series of ex-
periments, supernatants (3.5 
 
3
 
 10
 
5
 
 
 
g
 
, 60 min, 4
 
8
 
C) of liposomes
were supplemented with bovine serum albumin (6 
 
m
 
g/ml), pre-
cipitated with 80% acetone (80%, overnight, 4
 
8
 
C, centrifugation:
1.4 
 
3
 
 10
 
3
 
 60 min at 4
 
8
 
C), and examined for the release of cyto-
chrome 
 
c.
 
 Two-dimensional electrophoresis was performed after
standard protocols using a Pharmacia (Piscataway, NJ) ampholyte
(1%, pH 3–10; reference 39).
 
Cytofluorometric Analysis of PTPC Liposomes.
 
10-
 
ml aliquots (z107)
of liposomes were incubated during 15 min at RT in 125 mM
sucrose 1 10 mM Hepes (pH 7.4) supplemented with the indi-
cated dose of PT inducers (Atr, CaCl2, diazenedicarboxylic acid bis
5N,N-dimethylamide [diamide], ter-butylhydroperoxide) and/or
PT inhibitors (bongkrekic acid; cyclosporin A, N-methyl-Val-4-
cyclosporin A [provided by Sandoz, Basel, Switzerland]; and
monochlorobiman [Molecular Probes]). Alternatively, liposomes
were incubated during 15 min at 378C in the presence of the in-
dicated dose of active or inhibitor-inactivated caspases. Diluted
(1 ml) liposomes were incubated with 3,39dihexylocarbocyanine io-
dide [DiOC6(3), 80 nM, 20–30 min at RT; Molecular Probes],
followed by analysis of DiOC6(3) retention in a FACSÒ-Vantage
cytofluorometer (Becton Dickinson, San José, CA). The forward
scatter threshold was set at 30 (Amp 16) and the flow-rate at
1,500 events/s. The photomultiplyer of the side scatter and FL1
were set at 700 mV and 700–800 mV, respectively. The fluores-
cence was excited with an Argon laser (excitation wavelength
488 nm) and analyzed in FL-1 (wave length 530 6 30 nm). The
forward and side scatters were gated on the quantitatively most
abundant population of liposomes while excluding background
noise. Calibration with carboxylate microspheres (Fluoresbrite
BB; Polyscience, Warrington, PA) of defined diameters was used
to determine the diameter of liposomes that were gated on (gate:
150 to 300 nm; mean size of liposomes: 230 6 60 nm; X 6 SD
for 5 3 104 events). Electron microscopy confirmed the presence
of mostly unilamellar proteoliposomes of the expected size in the
PTPC liposome preparation. Triplicates of 5 3 104 liposomes
were analyzed for each data point. Results were expressed as per-
cent of reduction of DiOC6(3) fluorescence (log scale, geometric
mean), considering the reduction obtained with 0.25% SDS (15
min, RT) in PTPC liposomes as 100% value.
Evaluation of Caspase Effects on Isolated Mitochondria. Purified
mouse liver mitochondria were incubated in 10 mM Tris-MOPS
Figure 1. Enrichment of the PTPC. (A) Steps of
the purification process. For details consult Materi-
als and Methods. (B) Typical profile of an anion ex-
change chromatography performed on Triton-solu-
ble proteins (A, 2). Hexokinase activity (solid line)
elutes from the DE52 resin at a KCl concentration
(linear gradient, dotted line) of 190 6 10 mM. The
most active fractions (bar) are recovered (A, 3) and
reconstituted in liposomes as outlined in A. Cyto-
chrome c elutes from the gradient with the major
protein peak, at 70 6 10 mM (arrow). (C) Typical
profile of a molecular weight chromatography per-
formed on liposomes reconstituted with the frac-
tions recovered in B (A, 3). Note that hexokinase
activity accumulates in a few fractions of the lipo-
some–protein mixture. The fraction containing
maximum hexokinase activity constitutes the PTPC
liposomes (A, 4). (D) Immunochemical detection
of proteins contained in PTPC. Proteins from suc-
cessive steps of the purification procedure (A) were
analyzed by Western blot for the presence of the in-
dicated proteins. Proteins extracted from PTPC li-
posomes constitute the final step (A, 4) of the puri-
fication procedure. Results are representative for 22
(B and C), and two to three (D) independent deter-
minations.1264 Permeability Transition Pore Complex in Apoptosis
1 100 mM NH4Cl 1 10 mM EGTA (pH 7.2) during 30 min at
RT in the presence of different caspases. The supernatant (1.5 3
105 g) of these mitochondria was stored at 2808C until testing for
apoptogenic activity on isolated HeLa nuclei (90 min, 378C,
RT). DNA fragmentation was quantified by propidium iodine
staining (10 mg/ml, >5 min at RT) and cytofluorometric analysis
in an EPICS Prolife II (Coulter, Hialeah, FL), as described (26).
Results were expressed as the percentage of subdiploid nuclei, af-
ter subtraction of values obtained with buffer only (,20%). For
control purposes, different caspase inhibitors (Ac-DEVD.cmk,
Ac-YVAD.cmk, or Z-VAD.fmk (N-benzyloxycarbonyl-Val-Ala-
Asp-fluoromethylketone); 100 mM final concentration) were added
to the mitochondrial supernatant 15 min before determination of
apoptogenic activity. Aliquots of caspase-treated mitochondria
were resuspended in 400 mM mannitol, 50 mM Tris (HCl, pH
7.2), 5 mg/ml BSA, 10 mM KH2PO4, and 5 mM succinate, and
then labeled with DiOC6(3) (100 nM, 15 min at RT) and sub-
jected to cytofluorometric analysis using carbonylcyanide m-chlo-
rophenylhydrazone (CCCP; 50 mM) or Atr (5 mM) as positive
controls of maximum Dcm disruption.
Results
Reconstitution of the PTPC in Liposomes. Hexokinase 1 is
a cytosolic protein, part of which associates with the mito-
chondrial outer membrane where it binds to porin within
the contact site (22, 40–42). Taking advantage of this fact,
we traced the hexokinase activity copurifying with a protein
complex that is water insoluble in brain homogenates, par-
titions into the triton-soluble fraction, elutes from an anion
exchange FPLC column at a relatively high salinity, and in-
corporates into phosphatidylcholine/cholesterol liposomes
(Fig. 1 A–C). When comparing the abundance of proteins
extracted from liposomes incorporating hexokinase activity
with that of the preceding purification steps, it appears that
some proteins are selectively enriched (cyclophilin D, the
z60-kD isoform of the ANT, Bax, Bag-1), whereas some
are reduced (VDAC, F1 ATPase) or eliminated below the
limit of detection (Bcl-XL, Bcl-2, Bad, cytochrome c,
hsp60; Fig. 1 D). As shown by two-dimensional gel elec-
trophoresis, PTPC liposomes contain a limited set of pro-
teins whose complete identification is still in progress (Fig.
2). PTPC-containing liposomes can be treated with induc-
ers of PT pore opening, which cause the release of encap-
sulated molecules such as malate (106 daltons) and ATP
(509 daltons) (22, 43). Similarly, the fluorochrome calcein
(622 daltons), a hydrophilic polyanionic fluorochrome pre-
viously used to measure PT pore opening in intact cells
(44), can be encapsulated into PTPC liposomes and then
released by incubation with the ANT ligand Atr, a potent
inducer of PT pore opening (Fig. 3 A). This effect is pre-
vented by another ANT ligand, bongkrekic acid, which in-
hibits PT pore opening (Fig. 3 A). We have developed an-
other approach to quantify PT pore opening induced in
PTPC liposomes. Liposomes were equilibrated with the
amphophilic cationic fluorochrome DiOC6(3) (573 dal-
tons). The retention of DiOC6(3) fluorescence was then
monitored in a cytofluorometer (that is, in a flow in which
liposomes are diluted and the external DiOC6(3) concen-
tration approaches 0), whereas gating on a population of li-
posomes with defined forward and side scatter characteris-
tics (estimated diameter: 0.15–0.3 mm). When using this
approach, we found an Atr-induced shift in DiOC6(3) re-
tention, suggesting that most if not all proteoliposomes
found in this population contain a PT pore. PT pore open-
ing does not provoke a change in the average size (forward
scatter) of liposomes, nor does it affect their ultrastructure.
A good correlation was found between the release of small
molecules (ATP, malate, calcein) measured in bulk experi-
ments and the DiOC6(3) release measured by cytofluorom-
etry (Fig. 3; references 22, 43; and unpublished data). This
suggests that all these molecules can be released through the
PT pore, in accord with its reported molecular cut off of
1,500 daltons (12). The baseline DiOC6(3) incorporation
was the same in liposomes containing functional PTPC
(mean fluorescence channel 593 6 53, X 6 SEM, n 5 3) as
that observed in control liposomes (mean channel 601 6
43) (Fig. 3 B), indicating that the PT pore is constitutively
closed. PTPC-containing liposomes release DiOC6(3) in
response to several agents that induce PT in intact mito-
chondria (Atr, ter-butylhydroperoxide, Ca21, diamide), with
inhibitory effects of bongkrekic acid, monochlorobiman, cy-
closporin A, and N-methyl-Val-4-cyclosporin A, a nonim-
munosuppressive cyclophilin D ligand not acting on cal-
cineurin (Fig. 3 C). These findings emphasize the functional
similarity between the natural (mitochondrial) PTPC (8,
12) and the reconstituted (liposomal) PTPC (Fig. 3). More-
over, they confirm that the ANT (target of bongkrekic acid
and atractyloside), cyclophilin D (target of cyclosporin A
and N-methyl-Val-4-cyclosporin), and redox-sensitive SH
Figure 2. Two-dimensional gel electrophoresis of proteins extracted
from PTPC liposomes (Fig. 1 A, 4). Silver-stained proteins whose abun-
dance is consistently (three experiments) reduced upon digestion with
caspase 1 (1.5 U/ml) are marked in rectangles. Results are representative
for three independent experiments.1265 Marzo et al.
groups (target of diamide and monochlorobiman), as well as
Ca21-sensitive sites, participate in the regulation of the
PTPC (12, 13, 20–23).
Effect of Recombinant Bcl-2 and Bcl-XL on PTPC. Under
the conditions of fractionation described in Fig. 1, a proap-
optotic member of the Bcl-2 family (Bax) selectively coen-
riches with components of PTPC, whereas several antiapop-
totic members of the Bcl-2 family do not (Bcl-XL, Bcl-2;
Fig. 1 D). We therefore investigated the effect of antiapop-
totic members of the Bcl-2 family on PTPC. Recombinant
Bcl-2 and Bcl-XL proteins, as well as mutant Bcl-2 pro-
teins, were incorporated into liposomes together with
PTPC via dialysis, a procedure that allows for the oriented,
pH-independent incorporation of proteins into lipid mem-
branes (45, 46). Irrespective of the presence of Bcl-2–like
proteins, all liposome preparations consistently (n 5 12)
maintained a similar baseline DiOC6(3) fluorescence (mean
fluorescence channel 620 6 18 and 616 6 19 in the pres-
ence or absence of Bcl-2, respectively, X 6 SEM, 12 inde-
pendent experiments), with comparable SDS-releasable
DiOC6(3) release (Fig. 4 A) for as long as 8 h (not shown),
suggesting that Bcl-2 does not augment the membrane per-
meability in this experimental system. Moreover, Bcl-2
does not perturb the ultrastructure of PTPC liposomes or
their protein composition (not shown). The presence of
Bcl-XL or Bcl-2 protected against the DiOC6(3) release in-
duced by atractyloside, ter-butylhydroperoxide, as well as
low doses of Ca21, but not by diamide (Fig. 4 C). Similar
results were obtained, when instead of DiOC6(3) retention,
calcein efflux was studied (not shown). These effects corre-
late with the functional potency of Bcl-2, which protects
cells against most PT inducers (8, 9, 47), but not against di-
amide (8, 9). A Bcl-2 deletion mutant lacking a putative
channel-forming domain corresponding to the a5 and a6
helices, Bcl-2Da5/6, which has lost its antiapoptotic func-
tion (34), failed to prevent the DiOC6(3) release. In addi-
tion, a Bcl-2 point mutant in the BH1 region, Bcl-2
(Gly145Ala), which does not interact with Bax, failed to
protect against apoptosis (48) and had no inhibitory effect
on PTPC liposomes (Fig. 4 C). Altogether, these findings
suggest that Bcl-2 can regulate membrane permeability by
acting on or in concert with PTPC.
Effect of Recombinant Caspases on PTPC. Since caspases are
involved at all stages of apoptosis (5, 26, 49–51), we tested
whether caspases might act on PTPC. PTPC reconstituted
in liposomes were exposed to recombinant caspases, fol-
Figure 3. Function of recon-
stituted PTPC pores. (A) Re-
lease of calcein from PTPC-con-
taining liposomes incubated with
two antagonistic ANT ligands.
Calcein-loaded PTPC lipo-
somes were incubated with the
indicated dose of Atr and/or
bongkrekic acid (50 mM), fol-
lowed by fluorometric determi-
nation of the calcein release into
the supernatant. (B) Cytofluoro-
metric profile of liposomes la-
beled with the potential-sensitive
fluorochrome DiOC6(3). Lipo-
somes were reconstituted either
in the presence of the hexoki-
nase-containing fraction (PTPC
liposomes) or in its absence (con-
trol liposomes), treated with SDS
(0.25%), Atr (25 mM), and/or
bongkrekic acid (BA; 50 mM),
followed by DiOC6(3) staining
and cytofluorometric analysis.
(C) PTPC liposomes treated
with PT inducers (Atr [25 mM],
CaCl2[25  mM], diamide [500
mM] or ter-butylhydroperoxide
[tBHP, 500 mM]) and/or PT in-
hibitors (bongkrekic acid [BA; 50
mM], cyclosporin A [CsA; 10
mM],  N-methyl-4-Val-CsA [mod.
CsA; 10 mM], or monochlorobi-
man [MCB; 50 mM]). Results
are expressed as percentage (X 6
SD of triplicates) of the DiOC6(3)
release induced by 0.25% SDS.
Results are representative for at
least three independent determi-
nations.1266 Permeability Transition Pore Complex in Apoptosis
lowed by determination of the DiOC6(3) retention. Several
caspases induced DiOC6(3) release in a dose-dependent fash-
ion (Fig. 5, A and B). This effect was only obtained in PTPC-
containing liposomes, but not in control liposomes (not
shown). Tetrapeptide inhibitors of caspases (Ac-YVAD.cmk
for caspases 1 and 4 and Ac-DEVD.cmk for caspases 2, 3,
and 6) abolish caspase-induced DiOC6(3) release, suggest-
ing that this effect involves proteolysis rather than nonen-
zymatic protein interactions (Fig. 5, A and B). Accordingly,
two-dimensional gel electrophoresis of proteins extracted
from PTPC liposomes suggest several unidentified proteins
to be caspase 1 substrates (Fig. 2). The same caspases that
release DiOC6(3) from PTPC liposomes also disrupt the
Dcm in isolated liver mitochondria (Fig. 5 C) and release
AIF, which causes isolated nuclei to undergo DNA frag-
mentation (Fig. 5 D). Bcl-2 and Bcl-XL incorporated into
liposomes reduce the caspase-induced DiOC6(3) release,
whereas inactive Bcl-2 mutants (Bcl-2Da5/6 and Bcl-
2(Gly145Ala) fail to stabilize PTPC (Fig. 6, A and B). This
Bcl-2 effect can be at least partially overcome by high
caspase concentrations. Thus, in addition to stabilizing PTPC
liposomes exposed to Atr, ter-butylhydroperoxide and cal-
cium (Fig. 4), Bcl-2, and Bcl-XL partially suppress caspase-
induced DiOC6(3) release (Fig. 6).
Failure of PTPC to Release Cytochrome c. Since induction
of PTPC in intact mitochondria causes cytochrome c re-
lease (14, 15; and unpublished data), and since several
groups have suggested that Bcl-2 primarily regulates the re-
lease of cytochrome c via the outer mitochondrial mem-
brane rather than PT (6, 7, 31, 52), we investigated the pu-
tative relationship between PT pore opening and cytochrome
c. Incorporation of purified cytochrome c into PTPC lipo-
somes (which constitutively are devoid of cytochrome c,
Fig. 1 D) does not alter their functional behavior. Thus,
PTPC liposomes containing cytochrome c exhibit a normal
baseline level of DiOC6(3) retention and release DiOC6(3)
in response to Atr and caspases in a Bcl-2–inhibitable fash-
ion (Fig. 7 A). Although such liposomes contain significant
amounts of SDS-releasable cytochrome c, they fully retain
cytochrome c when incubated with doses of Atr or caspase
that cause DiOC6(3) release (Fig. 7 B). This indicates that
PTPC are not directly responsible for the release of cyto-
chrome c.
Discussion
Functional Equivalence of Natural and Reconstituted PTPC:
A Target of Multiple Effectors Including Caspases. PTPCs are
formed at the mitochondrial inner/outer membrane con-
tact site where they function as a Ca21-, voltage-, pH-, and
redox-gated channel with several levels of conductance
(12, 13, 19). In this work, we report the functional analysis
of PTPC enriched from brain homogenates and reconsti-
tuted in liposomes. Although the exact molecular composition
of PTPC remains to be defined, the functional exploration
of PTPC (Fig. 3) suggests that it does contain functionally
interconnected sites of interaction with bongkrekic acid
and Atr (two ligands of the ANT and perhaps other mem-
Figure 4. Effects of Bcl-2 on
PTPC. Hexokinase-enriched
fractions (Fig. 1 A, 3) were in-
corporated into liposomes by di-
alysis in the presence or absence
of recombinant Bcl-2, Bcl-2
(Gly145Ala), Bcl-2Da5/6, or
Bcl-XL, followed by functional
analysis. (A) Representative fluo-
rescence profiles of control
PTPC and Bcl-2 PTPC lipo-
somes treated with buffer only
(control), SDS, or Atr, followed
by incubation with DiOC6(3).
Note the absence of Atr effects
in Bcl-2 PTPC liposomes. (B)
Incorporation of native and mu-
tant Bcl-2 proteins into lipo-
somes. Proteins were extracted
from PTPC liposomes prepared
in the presence or absence of the
indicated Bcl-2 mutant, followed
by immunochemical quantita-
tion of Bcl-2 with a monoclonal
antibody that recognizes an
epitope (residues 20-34) not af-
fected by the mutations. (C)
Functional impact of Bcl-2 and
Bcl-XL. The different PTPC lipo-
some preparations were treated
with Atr (25 mM), CaCl2 (25 mM), diamide (500 mM), or ter-butylhydroperoxide (tBHP, 500 mM) to determine the DiOC6(3) release. Results are rep-
resentative for three to five independent experiments. 100% DiOC6(3) release was defined as the SDS-induced reduction of DiOC6(3) fluorescence ob-
served in PTPC liposomes generated in the absence of Bcl-2 or Bcl-XL.1267 Marzo et al.
bers of the mitochondrial carrier family), cytochrome c and
N-methyl-4-Val cytochrome c (two ligands of the cyclo-
philin D), diamide, and monochlorobimane (which act on
thiol residues), as well as Ca21. Accordingly, we detected
the ANT, cyclophilin D, and additional molecules previ-
ously suggested to associate with the ANT, namely porin
and hexokinase, in the PTPC (Fig. 1). In addition to these
molecules, PTPCs purify with Bax, Bag-1, F1-ATPase (Fig.
1 D), and several nonidentified proteins (Fig. 2) whose im-
pact on PTPC remains unclear. However, the functional
data indicate that PTPC liposomes regulate membrane per-
meability in a fashion that resembles the PT pore found in
Figure 5. Effect of caspases on
PTPC liposomes and isolated
mitochondria. (A) Representa-
tive DiOC6(3) fluorescence his-
tograms obtained after treatment
of liposomes with various
caspases (1.2 U/ml for caspase 1,
10 U/ml for caspase 6) in the
presence or absence of the indi-
cated caspase inhibitor (100
mM). (B) Dose dependency of
effects obtained with different
recombinant caspases on PTPC
liposomes. (C) Effect of caspases
on the Dcm. Mitochondria were
treated during 30 min with 5 U
caspase/200 ml, followed by de-
termination of the Dcm using
DiOC6(3). The protonophore
m-chlorophenylhydrazone (50
mM) defined 100% Dcm disrup-
tion. (D) Release of AIF into the
mitochondrial supernatant. Intact
mitochondria were treated with
the indicated caspase (5 U/200
ml), followed by centrifugation
and removal of the supernatant
that was tested for apoptogenic
activity on isolated HeLa nuclei.
The incubation was performed
in the presence of tetrapeptide
inhibitors (which inhibit caspases but not AIF) or in the presence of Z-VAD.fmk (which inhibits AIF) to exclude that nuclear DNA degradation is a di-
rect caspase effect. Similar results were obtained with mouse and rat (not shown) hepatocyte mitochondria.
Figure 6. Effect of Bcl-2 on
the caspase induced DiOC6(3)
release observed in PTPC lipo-
somes. (A) Representative
DiOC6(3) staining profiles. Lipo-
somes were generated in the
presence of recombinant Bcl-2,
Bcl-XL, and the indicated Bcl-2
mutants, treated with 1 U caspase
1, and labeled with DiOC6(3) to
determine the DiOC6(3) release.
Results are representative for at
least three independent determi-
nations. (B) Dose response curves
of caspase effects on liposomes
containing Bcl-XL, Bcl-2, or
Bcl-2 mutants.1268 Permeability Transition Pore Complex in Apoptosis
mitochondria. Thus, using a number of different inducers
and inhibitors of PT, we found an approximate functional
equivalence between the natural (mitochondrial) PTPC
and the reconstituted (liposomal) PTPC (Fig. 3) in the reg-
ulation of membrane permeability. Both in mitochondria
and in PTPC liposomes, a similar panel of agents acts to
permeabilize membranes (Ca21, Atr, prooxidants, and dia-
mide) or to stabilize membrane function (cyclosporin A,
monochlorobiman, and bongkrekic acid; references 8, 12,
Fig. 3). Thus, the protocol for PTPC enrichment and in-
corporation into liposomes yields a reduced experimental
system in which their function can be analyzed without in-
terference by other mitochondrial structures.
The equivalence between the natural and the reconsti-
tuted PTPC also extends to the fact that caspases disrupt
the membrane permeability in both PTPC liposomes (Fig.
5, A and B) and intact mitochondria (Fig. 5, C and D).
This suggests, in line with previous observations (5, 26, 30,
49–51), that caspases act as facultative inducers of PT (e.g.,
caspase-1 activated after Fas/APO-1 cross-linking and per-
haps caspase 3 in neuronal development) in specific signal
transduction pathways. The molecular target(s) of caspases
within the PTPC remain(s) to be defined. Of note, caspases
are not only involved in the upstream premitochondrial
phase, but also in the downstream postmitochondrial stage
of apoptosis, when they are activated as a result of mito-
chondrial cytochrome c and AIF release (5–7, 26). Thus,
mitochondria and caspases may engage in a positive ampli-
fication loop in which caspases cause mitochondrial mem-
brane disruption, which in turn favors the release of
caspase-activating factors.
Bcl-2–related Proteins Act on PTPC. The data reported
in this paper indicate that Bcl-2 and Bcl-XL regulate PT by
directly acting on PTPC. It has been suggested that Bcl-2
and Bcl-XL would primarily act on the mitochondrial re-
lease of cytochrome c (6, 7, 52), which would be an event
upstream of (6, 31) or independent from (7) PT pore open-
ing. However, the PTPC reconstituted into liposomes do
not contain cytochrome c (Fig. 1, B and D), yet are regu-
lated by Bcl-2 and Bcl-XL, implying that Bcl-2/Bcl-XL af-
fect certain mitochondrial functions in a cytochrome c–inde-
pendent fashion. As shown in this work, the PTPC is not
the structure responsible for cytochrome c release (Fig. 7),
in line with previous estimations suggesting that the PTPC
has a molecular cut off of z1,500 daltons (12, 13). Two
speculative possibilities remain plausible. First, the primary
regulatory target of Bcl2/BclXL in the mitochondrion
could be the PTPC that, once opened, causes cytochrome c
release in an indirect fashion, either by activating a yet un-
known cytochrome c–specific transporter or by mechanically
disrupting the integrity of the outer mitochondrial mem-
brane, e.g., due to local distension of the mitochondrial
matrix (12–14, 53). Second, Bcl2/BclXL might affect
PTPC and cytochrome c independently from each other in
a pleiotropic fashion. In favor of this latter hypothesis,
BclXL has been reported to bind to cytochrome c (52), and
Bcl-2 might interact with cytochrome c via the mammalian
CED4 homologue (54).
Recombinant Bcl-2 and Bcl-XL incorporated into
PTPC liposomes inhibit the induction of PT by a variety of
inducers: the ANT ligand atractyloside, the prooxidant ter-
butylhydroperoxide, Ca21 (Fig. 4), and low doses of caspases
(Fig. 6). In contrast, Bcl-2 and Bcl-XL fail to protect PTPC
liposomes against diamide (Fig. 4 C), in line with the fact
that Bcl-2 is an inefficient inhibitor of diamide-induced
Dcm disruption, both in cells and in isolated mitochondria
(8, 9). Moreover, Bcl-2 fails to prevent the effects of high
doses of caspases (Fig. 6), in accord with our previous ob-
servation that Bcl-2 present in mitochondria from human
CEM-C7 T lymphoma cells fails to counteract caspase
1–induced PT and apoptosis (26). The finding that these
Bcl-2 and Bcl-XL effects can be overcome by high, but not
by low, doses of caspses may resolve a controversy oppos-
ing models in which Bcl-2 homologues completely fail to
prevent Fas/APO-1 (caspase 1–dependent) apoptosis (26,
55–58) or, on the contrary, efficiently counteract caspase
1–mediated (59) or Fas/APO-1–triggered apoptosis (30,
60). Moreover, the fact that Bcl-2 mitigates the PT in-
duced by caspases that are broadly involved in apoptosis
(e.g., caspases 3 and 6) suggests that it can interrupt a self-
amplifying loop in which caspase effects on mitochondria
favor the release of caspase activators. We have investigated
whether Bcl-2 acts as an inhibitor of caspase-mediated di-
gestion of PTPC proteins. Our preliminary findings indi-
cate that Bcl-2 does not prevent the digestion of caspase 1
substrates (not shown), suggesting that it inhibits the func-
tional consequence of caspase 1–mediated proteolysis rather
than proteolysis itself. It has been shown recently that
caspase 3 cleaves Bcl-2, thereby converting it from a death
inhibitor to a death promoter (61). However, caspase 1
does not digest Bcl-2, at least in the conditions reported in
Fig. 6 A, suggesting the functional relevance of additional
caspase targets within the PTPC.
Crystallographic data (62) and studies of artificial mem-
branes containing Bcl-XL or Bcl-2 (33, 34) suggest that
Bcl-2–like proteins constitute ion channels. However, Bcl-
XL and Bcl-2 incorporated into membranes containing
PTPC, rather than increasing membrane permeability, sta-
bilize PTPC liposomes and prevent PT pore opening. This
apparent discrepancy may be explained by the composition
Figure 7. Cytochrome c re-
tention in PTPC liposomes. Li-
posomes were generated in the
absence or presence of recombi-
nant Bcl-2, followed by genera-
tion of a KCl-dependent ion
gradient and incorporation of cy-
tochrome c during the sonication
step. (A) Effect of SDS (0.25%),
Atr (50 mM), or caspases 1 or 3
(1 U), as determined by flow cy-
tometry after labeling with
DiOC6(3). (B) Supernatants of the liposomes treated as in A were sub-
jected to protein precipitation, followed by Western blot analysis of the
release of cytochrome c. Note that the blot has been overexposed. The
amount of cytochrome c released upon SDS treatment was estimated to
be 1 mg, and the detection limit of the immunoblot is z10 ng/lane.1269 Marzo et al.
of the artificial membranes, which only allow Bcl-2 to
form channels when they contain, in addition to neutral
lipids (as in this paper), an unusually high percentage (30–
40%) of acidic lipids (33, 34). At present, we cannot dis-
criminate between the possibilities that the PT-inhibitory
effect of Bcl-2 is due to interactions with and conforma-
tional effects on PTPC constituents, or rather due to the
specific neutralization of Bax (35, 48), a proapoptotic mol-
ecule that is present in PTPC (Fig. 1 D) and favors PT (32).
Irrespective of these possibilities, the Bcl-2 effect on PTPC
correlates with its antiapoptotic potential in the sense that
mutations or deletions abolishing the death antagonistic
potential of Bcl-2 also abrogate its PT-inhibitory function.
In addition to its PT-inhibitory effect, which may ac-
count for at least part of its cytoprotective action, Bcl-2 has
further pleiotropic effects (4, 10). Although some of these
effects, including those concerning the capacity of Bcl-2 to
affect redox regulation or intracellular Ca21 partition, may
be secondary to PT modulation; others are more difficult
to accommodate in a model in which the major action of
Bcl-2 would be PT regulation. This applies, in particular,
to the participation of Bcl-2 participation in a multiprotein
ensemble or “apoptosome” involving the mammalian
CED-4 homologue(s), cytochrome c, and large prodomain
caspases. As a possibility, Bcl-2 could exert a dual function
in which it simultaneously or sequentially acts on PTPC
and inactivates the apoptosome (10).
The Central Executioner of Apoptosis: Involvement of PT-
PC? Changes in mitochondrial membrane function have
been proposed to form part of the “central executioner”
(63), colloquially also referred to as “great integrator” or
“apostat” (2, 3, 6–8, 11). Activation of the central execu-
tioner during the effector stage would control the commit-
ment to undergo cell death and unify the many private in-
duction pathways of apoptosis into one common pathway.
The findings reported herein indicate that PTPC can con-
stitute a crossroad at which physiological modulators of PT
(Ca21, Mg21, pH, ADP, ATP, NAD(P)H, glutathione, cer-
amide, lipid oxidation products, etc.; references 12, 13, 19;
Fig. 3), caspases (Fig. 5), and Bcl-2 homologues (Fig. 4, 6)
together influence the fate of the cell. Thus, PTPC may si-
multaneously collect information on the metabolic stage of
the cell, signal transduction pathways, as well as on the
composition of the Bcl-2 complex. Opening of the PT
pore, which occurs almost universally during apoptosis, has
lethal repercussions including the mitochondrial generation
of reactive oxygen species, disruption of oxidative phos-
phorylation, and the mitochondrial release of apoptogenic
proteins necessary for the activation of downstream caspases
and endonuclease activation (1–10, 14, 15).
In conclusion, PTPC may be identical with or form part
of the critical structure that integrates different apoptosis
induction pathways, decides the fate of the cell, and coor-
dinates the common death program. If this interpretation is
correct, the future elucidation of the exact composition
and fine tuning of PTPC should furnish invaluable clues to
the understanding of the apoptotic process.
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